Nationwide turkish cohort study e.PULSE 347000+ pts Gender based comorbidity analysis Female asso w/ higher -accompanying CTD OR 3.75 -asthma OR 2.06 -depression OR 2.38 -fibromyalgia OR 3.16 and lesser - COPD OR 0.34 - ILD OR 0.60 -Malignancy OR 0.63 @RheumNow #EULAR2024 OP0175

When to administrate the PCV13 in RA? VACIMRA study 276pts randomized PCV13 + MTX = 75% humoral response PCV13 + MTX 1 month later = 88% humoral response No diff on dis control & GCs or DMARDs use #EULAR2024 @RheumNow AbstOP0140

#EULARBest @RheumNow https://t.co/cCv88iTCTV

MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PH 2/3 STUDY OF SHR0302, A SELECTIVE JAK 1 INHIBITOR, IN PATIENTS WITH ACTIVE AS - behaves like a JAK in AxSpA now as well as in RA - safety is clean/no new signals but where is the zoster? @RheumNow #EULAR2024

Baseline predictors of D2TRA in naive recent onset RA 1000pts -female sex -higher joint count -erosions -pulmonary involvement -depression -fatigue #EULAR24 AbstOP0118 @RheumNow

COMPARATIVE SAFETY OF JAK INHIBITORS VERSUS TNF OR IL-17 INHIBITORS FOR CARDIOVASCULAR DISEASE, VENOUS THROMBOEMBOLISM AND CANCER IN PSORIATIC ARTHRITIS AND AXIAL - no signal of significant difference but channeling bias last few years @RheumNow #EULAR2024

COMPARATIVE RISK OF MORTALITY IN NEW USERS OF PRESCRIPTION OPIOIDS FOR NON-CANCER PAIN: RESULTS FROM THE INTERNATIONAL PHARMACOSURVEILLANCE STUDY - HR 9-13 increased deaths narcotic use compared with codeine UK Boston Montreal >1 million pts included @RheumNow #EULAR2024

OP0202 looks at phenotypes of #RAILD in a cluster analysis 🌎Large multinational cohort 2⃣Two key clusters identified 📈Male sex, older age at RA & ILD onset, European ethnicity, smoking and CCP & RF positivity more frequent in cluster 1 vs 2 @RheumNow #EULAR2024 @Juge_P_A

RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty